Carlyle injects capital into Chinese lab operator

The private equity firm has invested in Adicon at a time when demand for private healthcare is growing in China.

Carlyle has bought a controlling stake in Adicon, winning a competitive auction for the Chinese clinical laboratory operator.

The private equity firm invested alongside Meinian Onehealth Healthcare, it said in a statement on Monday. Carlyle acquired a 13.5% stake in Meinian Onehealth Healthcare in 2012.

Last month, Meinian subsidiary Haimei Ai Investment Management signalled its intentions to buy a 5% stake in Adicon for $22 million, valuing the entire company at $440 million. It added that Adicon reported a net profit for the January to June period of Rmb40.8 million $5.9 million making the equity purchase’s valuation look steep.

The Chinese molecular diagnostics market...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222